Outstanding Outcome of Pancreatic Cancer: What Lessons Do We Learn

Pancreas (Fairfax, Va.) Pub Date : 2020-02-01 DOI:10.17140/POJ-4-E012

M. Saif

引用次数: 1

Abstract

The American Cancer Society’s estimates that 57,600 people (30,400 men and 27,200 women) will be diagnosed with pancreatic cancer in the United States for 2020 and approximately 47,050 people (24,640 men and 22,410 women) will die of pancreatic cancer in 2020.1 Despite advances in first-line therapy such as gemcitabine/nab-paclitaxel and fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFIRINOX) in advanced pancreatic cancer (aPC), median overall survival remains less than 12-months.2

查看原文本刊更多论文

胰腺癌的突出结果:我们吸取了什么教训

美国癌症协会估计，到2020年，美国将有57600人(30400名男性和27200名女性)被诊断为胰腺癌，到2020年将有大约47050人(24640名男性和22410名女性)死于胰腺癌。尽管吉西他滨/nab-紫杉醇、氟尿嘧啶、亚叶酸钙、奥沙利铂和伊立替康(FOLFIRINOX)等一线治疗方法在晚期胰腺癌(aPC)中取得了进展，但中位总生存期仍不到12个月

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Pancreas (Fairfax, Va.)

自引率

0.00%

发文量